Intersect ENT Inc (NASDAQ:XENT) COO Richard E. Kaufman sold 1,250 shares of the stock in a transaction dated Thursday, April 20th. The stock was sold at an average price of $17.25, for a total transaction of $21,562.50. Following the sale, the chief operating officer now directly owns 202,321 shares in the company, valued at approximately $3,490,037.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Intersect ENT Inc (NASDAQ:XENT) traded down 1.96% during mid-day trading on Friday, reaching $17.55. 275,677 shares of the company traded hands. Intersect ENT Inc has a 52-week low of $7.65 and a 52-week high of $20.64. The company’s market capitalization is $503.28 million. The firm’s 50 day moving average price is $16.09 and its 200-day moving average price is $13.76.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Tuesday, February 28th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.03. Intersect ENT had a negative return on equity of 21.25% and a negative net margin of 35.69%. The company had revenue of $24.20 million for the quarter, compared to analyst estimates of $23.47 million. During the same period in the prior year, the company posted ($0.20) EPS. Intersect ENT’s quarterly revenue was up 28.7% on a year-over-year basis. Equities analysts predict that Intersect ENT Inc will post ($0.79) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

COPYRIGHT VIOLATION NOTICE: “Richard E. Kaufman Sells 1,250 Shares of Intersect ENT Inc (XENT) Stock” was reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at http://www.financial-market-news.com/richard-e-kaufman-sells-1250-shares-of-intersect-ent-inc-xent-stock/1406500/.

Several institutional investors have recently made changes to their positions in XENT. Bayesian Capital Management LP acquired a new position in shares of Intersect ENT during the fourth quarter worth about $151,000. Moors & Cabot Inc. raised its position in shares of Intersect ENT by 0.9% in the third quarter. Moors & Cabot Inc. now owns 10,950 shares of the medical equipment provider’s stock worth $175,000 after buying an additional 100 shares during the last quarter. Tyers Asset Management LLC acquired a new position in shares of Intersect ENT during the fourth quarter worth about $200,000. Flinton Capital Management LLC acquired a new position in shares of Intersect ENT during the fourth quarter worth about $254,000. Finally, A.R.T. Advisors LLC acquired a new position in shares of Intersect ENT during the fourth quarter worth about $353,000. 77.81% of the stock is currently owned by institutional investors.

Several analysts have recently issued reports on XENT shares. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of Intersect ENT in a research report on Wednesday, January 11th. Canaccord Genuity reissued a “buy” rating and set a $16.00 price target on shares of Intersect ENT in a research report on Tuesday, February 21st. Deutsche Bank AG raised shares of Intersect ENT from a “hold” rating to a “buy” rating and increased their price target for the stock from $15.00 to $19.00 in a research report on Monday, March 6th. Northland Securities reissued a “buy” rating and set a $17.00 price target on shares of Intersect ENT in a research report on Monday, March 13th. Finally, Zacks Investment Research cut shares of Intersect ENT from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. Intersect ENT presently has a consensus rating of “Buy” and a consensus target price of $18.00.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

5 Day Chart for NASDAQ:XENT

Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with MarketBeat.com's FREE daily email newsletter.